Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TriSalus Life Sciences was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our companyâ¿¿s heritage is in the development of devices for our Pressure-Enabled Drug Deliveryâ¿¢ (PEDDâ¿¢) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy.
| Last: | $5.025 |
|---|---|
| Change Percent: | -3.55% |
| Open: | $5.31 |
| Close: | $5.21 |
| High: | $5.365 |
| Low: | $5.01 |
| Volume: | 41,643 |
| Last Trade Date Time: | 02/27/2026 12:45:15 pm |
| Market Cap: | $227,337,615 |
|---|---|
| Float: | 36,224,125 |
| Insiders Ownership: | 3.04% |
| Institutions: | 18 |
| Short Percent: | N/A |
| Industry: | Medical Equipment & Supplies |
| Sector: | Healthcare |
| Website: | https://www.trisaluslifesci.com |
| Country: | US |
| City: | Westminster |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about TriSalus Life Sciences Inc. (NASDAQ: TLSI).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
